消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2021 MONITORED共识：炎症性肠病患者的肾功能监测

2021-12-02 国外消化科相关专家小组（统称） Dig Liver Dis

炎症性肠病

炎症性肠病（IBD）患者存在药物相关肾脏毒性风险和肾脏项的肠外表现，应对患者进行相应监测。炎症性肠病肾功能监测(MONITORED)倡议达成了IBD患者肾功能监测共识，提出了相应的监测方法。

中文标题：

2021 MONITORED共识：炎症性肠病患者的肾功能监测

英文标题：

Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus

发布机构：

国外消化科相关专家小组（统称）

发布日期：

2021-12-02

简要介绍：

炎症性肠病（IBD）患者存在药物相关肾脏毒性风险和肾脏项的肠外表现，应对患者进行相应监测。炎症性肠病肾功能监测(MONITORED)倡议达成了IBD患者肾功能监测共识，提出了相应的监测方法。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 MONITORED共识：炎症性肠病患者的肾功能监测.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5dbba1c002285eef, title=2021 MONITORED共识：炎症性肠病患者的肾功能监测, enTitle=Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus, guiderFrom=Dig Liver Dis, authorId=0, author=, summary=炎症性肠病（IBD）患者存在药物相关肾脏毒性风险和肾脏项的肠外表现，应对患者进行相应监测。炎症性肠病肾功能监测(MONITORED)倡议达成了IBD患者肾功能监测共识，提出了相应的监测方法。, cover=https://img.medsci.cn/2021127/1638873388966_5579292.png, journalId=0, articlesId=null, associationId=950, associationName=国外消化科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Thu Dec 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">炎症性肠病（IBD）患者存在药物相关肾脏毒性风险和肾脏项的肠外表现，应对患者进行相应监测。炎症性肠病肾功能监测(MONITORED)倡议达成了IBD患者肾功能监测共识，提出了相应的监测方法。</span></p>, tagList=[TagDto(tagId=1125, tagName=炎症性肠病)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1125, guiderKeyword=炎症性肠病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2072, appHits=87, showAppHits=0, pcHits=257, showPcHits=1985, likes=1, shares=15, comments=7, approvalStatus=1, publishedTime=Tue Dec 07 18:42:26 CST 2021, publishedTimeString=2021-12-02, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Dec 07 18:42:15 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 09:58:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 MONITORED共识：炎症性肠病患者的肾功能监测.pdf)])
2021 MONITORED共识：炎症性肠病患者的肾功能监测.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198160, encodeId=1e791198160e5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Mon Feb 28 21:35:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186080, encodeId=e16f11860809d, content=学习资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa0b6157897, createdName=ms3000000098940767, createdTime=Wed Jan 19 17:15:15 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082351, encodeId=3f2e1082351a3, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:18 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080208, encodeId=3a0b1080208c5, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Wed Dec 15 08:51:24 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078287, encodeId=861910e8287c9, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 09 06:59:43 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2022-02-28 freegut

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198160, encodeId=1e791198160e5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Mon Feb 28 21:35:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186080, encodeId=e16f11860809d, content=学习资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa0b6157897, createdName=ms3000000098940767, createdTime=Wed Jan 19 17:15:15 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082351, encodeId=3f2e1082351a3, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:18 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080208, encodeId=3a0b1080208c5, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Wed Dec 15 08:51:24 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078287, encodeId=861910e8287c9, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 09 06:59:43 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2022-01-19 ms3000000098940767

    学习资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198160, encodeId=1e791198160e5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Mon Feb 28 21:35:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186080, encodeId=e16f11860809d, content=学习资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa0b6157897, createdName=ms3000000098940767, createdTime=Wed Jan 19 17:15:15 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082351, encodeId=3f2e1082351a3, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:18 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080208, encodeId=3a0b1080208c5, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Wed Dec 15 08:51:24 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078287, encodeId=861910e8287c9, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 09 06:59:43 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-21 龙珠

    学习好资料！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198160, encodeId=1e791198160e5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Mon Feb 28 21:35:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186080, encodeId=e16f11860809d, content=学习资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa0b6157897, createdName=ms3000000098940767, createdTime=Wed Jan 19 17:15:15 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082351, encodeId=3f2e1082351a3, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:18 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080208, encodeId=3a0b1080208c5, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Wed Dec 15 08:51:24 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078287, encodeId=861910e8287c9, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 09 06:59:43 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-15 刘晓捷

    受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1198160, encodeId=1e791198160e5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c891547870, createdName=freegut, createdTime=Mon Feb 28 21:35:25 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186080, encodeId=e16f11860809d, content=学习资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa0b6157897, createdName=ms3000000098940767, createdTime=Wed Jan 19 17:15:15 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082351, encodeId=3f2e1082351a3, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:39:18 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080208, encodeId=3a0b1080208c5, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=LFRRP6YqrAia0BryFmv6ibnA&s=100&t=1555426989, createdBy=79c45230339, createdName=刘晓捷, createdTime=Wed Dec 15 08:51:24 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078287, encodeId=861910e8287c9, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 09 06:59:43 CST 2021, time=2021-12-09, status=1, ipAttribution=)]
    2021-12-09 微探

    学习学习

    0

相关指南

2021 意大利共识声明：促进炎症性肠病患者的心理社会健康

国外精神科相关专家小组（统称） · 2021-11-28

2021 CAG临床实践指南：炎症性肠病患者免疫接种—第2部分：灭活疫苗

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2021-08-01

2021 CAG临床实践指南：炎症性肠病患者免疫接种—第1部分：活疫苗

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2021-02-19

2021 WSES/AAST指南：炎症性肠病的急诊管理

世界急诊外科学会(WSES,World Society of Emergency Surgery) · 2021-05-11

2021 国际共识：炎症性肠病患者静脉和动脉血栓性事件的预防

国外消化科相关专家小组（统称） · 2021-08-27

关于炎症性肠病静脉血栓栓塞风险、预防和治疗的共识声明：加拿大胃肠病学协会

美国胸科医师学会(ACCP,American College of Chest Physicians) · 2021-09-01

拓展阅读

2014年加拿大炎症性肠病（IBD）与静脉血栓防治共识意见：加拿大胃肠病学会

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-03-01

2014 ESPGHAN儿童和青少年炎症性肠病诊断的波尔图标准（修订版）

欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN,European Society for Paediatric Gastroenterology, Hepatology, and Nutrition) · 2014-06-10

2014 CAG立场声明：应用巯嘌呤类药物治疗炎症性肠病

加拿大胃肠病学协会(CAG,The Canadian Association of Gastroenterology) · 2014-07-04

2015 ASGE指南：内镜检查在炎症性肠病中的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2015-03-20

2016 建立我国炎症性肠病诊治中心质量控制指标的共识

中华医学会消化病学分会炎症性肠病学组 · 2016-07-30

2017 IG-IBD临床实践指南：应用糖皮质激素和免疫抑制药物治疗炎症性肠病

意大利炎症性肠病研究组(IG-IBD,Italian Group for the Study of Inflammatory Bowel Disease) · 2017-01-25